---
layout: post
title: "Schedules of Controlled Substances: Placement of Brorphine in Schedule I; Correction"
date: 2026-02-05 18:56:10 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-15249
original_published: 2023-07-19 00:00:00 +0000
significance: 8.00
---

# Schedules of Controlled Substances: Placement of Brorphine in Schedule I; Correction

**Published:** February 05, 2026 18:56 UTC
**Source:** Federal Register
**Original Published:** July 19, 2023 00:00 UTC
**Document Number:** 2023-15249

## Summary

On March 6, 2023, the Drug Enforcement Administration published a final order placing 1-(1-(1-(4-bromophenyl)ethyl)piperidin- 4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (commonly known as brorphine), including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation, in schedule I of the Controlled Substances Act. In an amendatory instruction, the document incorrectly designated certain paragraphs. This document corrects that instruction.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/07/19/2023-15249/schedules-of-controlled-substances-placement-of-brorphine-in-schedule-i-correction)
- API: https://www.federalregister.gov/api/v1/documents/2023-15249

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
